Novartis Starlix Takes Aim At Diabetes Prevention With 8,000-Patient Study
Executive Summary
Novartis will seek a diabetes prevention claim for its type 2 diabetes therapy Starlix with data generated by an 8,000-patient outcomes study.
You may also be interested in...
Novartis Merger Stance: Firm "Prefers" No Deal For At Least Two Years
Novartis would "prefer" to wait two or three years before its next large transaction so it can focus on upcoming product launches, CFO Raymund Breu told the J.P. Morgan CEO conference on building shareholder value April 26.
Novartis Merger Stance: Firm "Prefers" No Deal For At Least Two Years
Novartis would "prefer" to wait two or three years before its next large transaction so it can focus on upcoming product launches, CFO Raymund Breu told the J.P. Morgan CEO conference on building shareholder value April 26.
Genentech Xolair Brand Awareness Reaches 55% Among Allergists
Brand awareness of Genentech's asthma drug Xolair (omalizumab) is over 50% among allergists as a result of Genentech's market preparation efforts, compared to 48% in the first quarter, Chief Operating Officer Myrtle Potter reported during an analyst meeting in New York City Feb. 21.